# A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Source: https://onco.cc/trials/nct07190248/  
OnCo record `nct07190248` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Calderasib in non-small-cell lung cancer, now recruiting.

## Summary

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) is a phase 3 interventional study registered as NCT07190248, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007). Planned enrolment is 675 participants (estimated). The study started in 2025-10-08 and primary completion is expected in 2029-12-07. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: KANDLELIT-007
- Tags: ctgov-ingest
- Registry id: NCT07190248
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
- Sponsor: Merck Sharp & Dohme
- Enrolled: 675

## Sources

- ClinicalTrials.gov NCT07190248: https://clinicaltrials.gov/study/NCT07190248

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Calderasib](https://onco.cc/drugs/calderasib/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07190248.json